| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Institut National de la Sante et de la Recherche Medicale, U697, Paris, France; 2 University of Virginia, Charlottesville, Virginia; and 3 UMR146 Centre National de Recherche Scientifique, Orsay, France
Requests for reprints: Alain Mauviel, Institut National de la Sante et de la Recherche Medicale U697, Pavillon Bazin, Hôpital Saint-Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France. Phone: 33-1-53-72-20-69; Fax: 33-1-53-72-20-51; E-mail: alain.mauviel{at}stlouis.inserm.fr.
Melanoma has a propensity to metastasize to bone, where it is exposed to high concentrations of transforming growth factor-ß (TGF-ß). Because TGF-ß promotes bone metastases from other solid tumors, such as breast cancer, we tested the role of TGF-ß in melanoma metastases to bone. 1205Lu melanoma cells, stably transfected to overexpress the natural TGF-ß/Smad signaling inhibitor Smad7, were studied in an experimental model of bone metastasis whereby tumor cells are inoculated into the left cardiac ventricle of nude mice. All mice bearing parental and mock-transfected 1205Lu cells developed osteolytic bone metastases 5 weeks post-tumor inoculation. Mice bearing 1205Lu-Smad7 tumors had significantly less osteolysis on radiographs and longer survival compared with parental and mock-transfected 1205Lu mice. To determine if the reduced bone metastases observed in mice bearing 1205Lu-Smad7 clones was due to reduced expression of TGF-ß target genes known to enhance metastases to bone from breast cancer cells, we analyzed gene expression of osteolytic factors, parathyroid hormone-related protein (PTHrP) and interleukin-11 (IL-11), the chemotactic receptor CXCR4, and osteopontin in 1205Lu cells. Quantitative reverse transcription-PCR analysis indicated that PTHrP, IL-11, CXCR4, and osteopontin mRNA steady-state levels were robustly increased in response to TGF-ß and that Smad7 and the TßRI small-molecule inhibitor, SB431542, prevented such induction. In addition, 1205Lu-Smad7 bone metastases expressed significantly lower levels of IL-11, connective tissue growth factor, and PTHrP. These data suggest that TGF-ß promotes osteolytic bone metastases due to melanoma by stimulating the expression of prometastatic factors via the Smad pathway. Blockade of TGF-ß signaling may be an effective treatment for melanoma metastasis to bone. [Cancer Res 2007;67(5):2317–24]
This article has been cited by other articles:
|
|
 |
|
  X. Yan, Z. Liu, and Y. Chen Regulation of TGF-{beta} signaling by Smad7 Acta Biochim Biophys Sin, April 1, 2009; 41(4): 263 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-S. Jeon, T. Dracheva, S.-H. Yang, D. Meerzaman, J. Fukuoka, A. Shakoori, K. Shilo, W. D. Travis, and J. Jen SMAD6 Contributes to Patient Survival in Non-Small Cell Lung Cancer and Its Knockdown Reestablishes TGF-{beta} Homeostasis in Lung Cancer Cells Cancer Res., December 1, 2008; 68(23): 9686 - 9692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Hoover and S. W. Kubalak Holding Their Own: The Noncanonical Roles of Smad Proteins Sci. Signal., November 18, 2008; 1(46): pe48 - pe48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tang, Z. Liu, L. Zhao, T. L. Clemens, and X. Cao Smad7 Stabilizes {beta}-Catenin Binding to E-cadherin Complex and Promotes Cell-Cell Adhesion J. Biol. Chem., August 29, 2008; 283(35): 23956 - 23963. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Le Scolan, Q. Zhu, L. Wang, A. Bandyopadhyay, D. Javelaud, A. Mauviel, L. Sun, and K. Luo Transforming Growth Factor-{beta} Suppresses the Ability of Ski to Inhibit Tumor Metastasis by Inducing Its Degradation Cancer Res., May 1, 2008; 68(9): 3277 - 3285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A Kingsley, P. G J Fournier, J. M Chirgwin, and T. A Guise Molecular Biology of Bone Metastasis Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 443 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. O'Neill, S. Seo, I. G. Serebriiskii, S. R. Lessin, and E. A. Golemis A New Central Scaffold for Metastasis: Parsing HEF1/Cas-L/NEDD9 Cancer Res., October 1, 2007; 67(19): 8975 - 8979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Kingsley, P. G.J. Fournier, J. M. Chirgwin, and T. A. Guise Molecular Biology of Bone Metastasis Mol. Cancer Ther., October 1, 2007; 6(10): 2609 - 2617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G.J. Fournier and T. A. Guise BMP7: A New Bone Metastases Prevention? Am. J. Pathol., September 1, 2007; 171(3): 739 - 743. [Full Text] [PDF]
|
|
|
|
|
|
S. Dennler, J. Andre, I. Alexaki, A. Li, T. Magnaldo, P. ten Dijke, X.-J. Wang, F. Verrecchia, and A. Mauviel Induction of Sonic Hedgehog Mediators by Transforming Growth Factor-{beta}: Smad3-Dependent Activation of Gli2 and Gli1 Expression In vitro and In vivo Cancer Res., July 15, 2007; 67(14): 6981 - 6986. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
